Literature DB >> 26009804

Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions.

A Gajofatto1,2, M Turatti3, M R Bianchi1,2, S Forlivesi1,2, F Gobbin1,2, A Azzarà4, S Monaco1,2, M D Benedetti2.   

Abstract

BACKGROUND: Benign multiple sclerosis (BMS) definitions rely on physical disability level but do not account sufficiently for cognitive impairment which, however, is not rare.
OBJECTIVE: To study the evolution of physical disability and cognitive performance of a group of patients with BMS followed at an University Hospital Multiple Sclerosis Center.
METHODS: A consecutive sample of 24 BMS cases (diagnosis according to 2005 McDonald's criteria, relapsing-remitting course, disease duration ≥ 10 years, and expanded disability status scale [EDSS] score ≤ 2.0) and 13 sex- and age-matched non-BMS patients differing from BMS cases for having EDSS score 2.5-5.5 were included. Main outcome measures were as follows: (i) baseline and 5-year follow-up cognitive impairment defined as failure of at least two tests of the administered neuropsychological battery; (ii) EDSS score worsening defined as confirmed increase ≥ 1 point (or 0.5 point if baseline EDSS score = 5.5).
RESULTS: At inclusion, BMS subjects were 41 ± 8 years old and had median EDSS score 1.5 (range 0-2), while non-BMS patients were 46 ± 8 years old and had median EDSS score 3.0 (2.5-5.5). At baseline 16% of patients in both groups were cognitively impaired. After 5 years, EDSS score worsened in 8% of BMS and 46% of non-BMS patients (P = 0.008), while the proportion of cognitively impaired subjects increased to 25% in both groups.
CONCLUSIONS: Patients with BMS had better physical disability outcome at 5 years compared to non-BMS cases. However, cognitive impairment frequency and decline over time appeared similar. Neuropsychological assessment is essential in patients with BMS given the distinct pathways followed by disease progression in cognitive and physical domains.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  benign course; cognitive impairment; multiple sclerosis; physical disability

Mesh:

Year:  2015        PMID: 26009804     DOI: 10.1111/ane.12442

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  Cytokine-chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement.

Authors:  Melis Şen; Ece Akbayır; Özlem Mercan; Erdil Arsoy; Mehmet Gencer; Vuslat Yılmaz; Cem İsmail Küçükali; Erdem Tüzün; Recai Türkoğlu
Journal:  J Spinal Cord Med       Date:  2019-09-26       Impact factor: 1.985

Review 2.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

3.  Impairment and restrictions in possibly benign multiple sclerosis.

Authors:  Laura Melanie Schaefer; Jana Poettgen; Anja Fischer; Stefan Gold; Jan-Patrick Stellmann; Christoph Heesen
Journal:  Brain Behav       Date:  2019-03-18       Impact factor: 2.708

Review 4.  Recommendations for cognitive screening and management in multiple sclerosis care.

Authors:  Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.